This page shows the result of browsing biomarker from different fieldss.For more information see HELP page.
The total number entries retrieved from this search are 52Biomarker ID | Biomarker | Biomolecule | Subject | Regulation | Biomarker's type | Experiment | Level of significance | Source | PMID |
---|---|---|---|---|---|---|---|---|---|
2056 | Putrescine, spermidine, spermine, N-acetylspermine and N-acetylspermidine | Metabolite | Human | Upregulated in the plasma of liver cancer patients than lung cancer patients | Diagnostic | HCC v/s Normal | p < 0.05 | Urine and Plasma | 27517900 |
2057 | Spermine, followed by N-acetylspermidine, putrescine, cadaverine, spermidine, N-acetylspermine and N-acetylputrescine | Metabolite | Human | Upregulated in the urine of liver cancer patients than lung cancer patients | Diagnostic | HCC v/s Normal | p < 0.05 | Urine and Plasma | 27517900 |
2060 | Uracil | Metabolite | Mice | Downregulated | Potential Predictive * | Cancer v/s Normal; Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2061 | cis-Aconitate acid | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2062 | D-4-Phosphopantothenate | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2063 | Progesterone | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2064 | 5-Thymidylic acid | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2065 | 2-Phospho-d-glyceric acid | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2066 | Niacinamide | Metabolite | Mice | Upregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2067 | Cortisone | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2068 | Imidazoleacetic acid ribotide | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2069 | 3-Methyl-2-oxovaleric acid | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2070 | Pseudoephedrine | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2071 | 4-Phosphopantothenoylcysteine | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2072 | Pantetheine 4-phosphate | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2073 | Hippuric acid | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2074 | 3-Hydroxyanthranilic acid | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2075 | Glycine | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2076 | Creatine | Metabolite | Mice | Upregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2077 | Cortisol | Metabolite | Mice | Upregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2078 | Allantoic acid | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2079 | Pantothenic acid | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2080 | Creatinine | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2081 | Urea | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2082 | 5-Hydroxyindoleacetic acid | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2083 | Phytosphingosine | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2084 | Imidazoleacetic acid riboside | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.01 | Urine and Plasma | 27077962 |
2130 | VTN | Protein | Human | Downregulated in HCV-infected HCC patients | Diagnostic | Normal vs HCV-infected HCC patients, Normals vs non HCV-infected HCC | p < 0.05 | Plasma | 23944848 |
2131 | SAP | Protein | Human | Downregulated in HCV-infected HCC patients | Diagnostic | Normal vs HCV-infected HCC patients, Normals vs non HCV-infected HCC | p < 0.01 | Plasma | 23944848 |
2164 | Apo-A4 | Protein | Human | Downregulated in HCC patients | Diagnostic | HCC v/s other liver disease (cirrhosis/ALD) | p < 0.01 | Plasma | 21160983 |
2165 | APO-A1 | Protein | Human | Upregulated in HCC patients | Diagnostic | HCC v/s other liver disease (cirrhosis/ALD) | p < 0.01 | Plasma | 21160983 |
2166 | APO-A1, Apo-A4 | Protein | Human | APO-A4 Upregulated and APO-A1 downregulated in HCC patients | Diagnostic | HCC v/s other liver disease (cirrhosis/ALD) | p < 0.01 | Plasma | 21160983 |
2179 | lamin B1 | Protein | Human | Upregulated in liver cancer patients | Diagnostic and Prognostic | Normal vs HCC; significantly associated with the increased number of tumor nodules , the size of tumors, and tumor stage | p < 0.01 | Plasma | 19522540 |
2181 | miR-101-3p, miR-106b-3p, miR-1246 | miRNA | Human | Upregulated in HCC | Diagnostic | HCC v/s Cirrhosis | p < 0.001 | Plasma | 29632649 |
2182 | miR-101-3p | miRNA | Human | Upregulated in HCC | Diagnostic | HCC v/s Cirrhosis | p < 0.001 | Plasma | 29632649 |
2183 | miR-1246 | miRNA | Human | Upregulated in HCC | Diagnostic | HCC v/s Cirrhosis | p < 0.001 | Plasma | 29632649 |
2184 | miR-106b-3p | miRNA | Human | Upregulated in HCC | Diagnostic | HCC v/s Cirrhosis | p < 0.001 | Plasma | 29632649 |
2185 | miR-101-3p, miR-106b-3p | miRNA | Human | Upregulated in HCC | Diagnostic | HCC v/s Cirrhosis | p < 0.001 | Plasma | 29632649 |
2186 | miR-101-3p, miR-1246 | miRNA | Human | Upregulated in HCC | Diagnostic | HCC v/s Cirrhosis | p < 0.001 | Plasma | 29632649 |
2187 | miR-106b-3p, miR-1246 | miRNA | Human | Upregulated in HCC | Diagnostic | HCC v/s Cirrhosis | p < 0.001 | Plasma | 29632649 |
2188 | miR-101-3p | miRNA | Human | Upregulated in HCC | Diagnostic | HCC v/s Control | p < 0.001 | Plasma | 29632649 |
2189 | miR-101-3p, miR-106b-3p, miR-1246 | miRNA | Human | Upregulated in HCC | Diagnostic | HCC v/s Control | p < 0.001 | Plasma | 29632649 |
2190 | miR-1246 | miRNA | Human | Upregulated in HCC | Diagnostic | HCC v/s Control | p < 0.001 | Plasma | 29632649 |
2191 | miR-106b-3p | miRNA | Human | Upregulated in HCC | Diagnostic | HCC v/s Control | p < 0.001 | Plasma | 29632649 |
2192 | miR-101-3p, miR-106b-3p | miRNA | Human | Upregulated in HCC | Diagnostic | HCC v/s Control | p < 0.001 | Plasma | 29632649 |
2193 | miR-101-3p, miR-1246 | miRNA | Human | Upregulated in HCC | Diagnostic | HCC v/s Control | p < 0.001 | Plasma | 29632649 |
2194 | miR-106b-3p, miR-1246 | miRNA | Human | Upregulated in HCC | Diagnostic | HCC v/s Control | p < 0.001 | Plasma | 29632649 |
2241 | DANCR | LncRNA | Human | Upregulated in HCC | Diagnostic and Prognostic | HCC v/s Normal/Cirrhosis/CHB;associated with metastasis of patients | p < 0.001 | Plasma | 27919960 |
2242 | RP11-160H22.5 | LncRNA | Human | Upregulated in HCC with Fold change >2.0 | Diagnostic | HCC v/s Normal | p < 0.01 | Plasma | 25714016 |
2243 | XLOC_014172 | LncRNA | Human | Upregulated in HCC with Fold change >2.1 | Diagnostic and Prognostic | HCC v/s Normal; associated with metastatsis of patients | p < 0.01 | Plasma | 25714016 |